PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 594791

Bilateral synchronous transitional ureteral carcinoma: two additional cases.

R L Levine·R A Airhart
View original source ↗Export metadata ↓

Abstract

Bilateral synchronous transitional ureteral carcinoma has previously been reported only 11 times. Herein, two additional cases are reported. Analysis shows these tumors to be of relatively low grade and low stage. It is necessary to fully evaluate the opposite side in a patient presenting with unilateral ureteral tumor. If bilateral disease is present, a conservative surgical procedure should be done.

Explore related subjects

Carcinoma, Transitional CellHumansMaleMiddle AgedNeoplasms, Multiple PrimaryUreterUreteral NeoplasmsCase ReportsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R L Levine, R A Airhart. 1977. Bilateral synchronous transitional ureteral carcinoma: two additional cases.. https://pubmed.ncbi.nlm.nih.gov/594791/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Trimodality treatment and selective organ preservation for bladder cancer.

Standard treatment for muscle-invasive bladder cancer is cystectomy. Trimodality treatment, including transurethral resection of the bladder tumor (TURBT), radiation therapy and chemotherapy, has been shown to produce survival rates comparable to those of cystectomy. With these programs, cystectomy has been reserved for patients with incomplete response or local relapse. During the past 15 years, organ preservation by trimodality treatment has been investigated in prospective series from single centers and cooperative groups, with more than 1,000 patients included. Five-year overall survival rates in the range of 50% to 60% have been reported, and approximately three quarters of the surviving patients maintained their bladder. Clinical criteria helpful in determining ideal patients for bladder preservation include early tumor stage (including high-risk T1 disease), a visibly complete TURBT, and absence of ureteral obstruction. Close coordination among all disciplines is required to achieve optimal results. Future investigations will focus on (1) optimizing radiation techniques and incorporating more effective systemic chemotherapy, and (2) the proper selection of patients based on molecular makers.

Carcinoma, Transitional Cell↗